The Carlat Psychiatry Podcast
PTSD 101: Nine Off-Label Meds
Sep 23, 2024
Delve into the intriguing world of off-label medications for PTSD, with a spotlight on a new contender awaiting FDA approval. Discover promising advances in antipsychotic treatments like Brexpiprazole and its partnership with sertraline. The conversation also tackles the complexities of treating insomnia tied to PTSD, weighing the pros and cons of medications like trazodone and benzodiazepines. Personalization in treatment is emphasized as crucial for effective management.
27:17
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Brexpiprazole's potential FDA approval as a PTSD treatment marks a significant shift towards more personalized pharmacological solutions in mental health care.
- The mixed outcomes of topiramate for PTSD underscore the need for cautious use, particularly in treatment-resistant cases and those with substance use issues.
Deep dives
Emerging Medication Options for PTSD
A new medication, Brexpiprazole, is being considered for FDA approval as a treatment for PTSD, particularly in conjunction with sertraline for patients who do not respond to antidepressants. Trials have shown Brexpiprazole to significantly improve various PTSD symptoms including re-experiencing, avoidance, and hyperarousal, though it did not overtly address issues with sleep. Its approval could shift the landscape of PTSD treatment away from traditional antipsychotics like risperidone, which have been the go-to option. This change highlights the evolving nature of PTSD treatment and the potential for more tailored pharmacological solutions.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
